Our Company
Built by people who've shipped industry-first diagnostics.
Founded on a simple observation: across three first-of-their-kind cancer diagnostic products, the right clinical samples were always the bottleneck. NGSS exists to remove it.
JF
Founder & CEO
Dr. Jesse Fox
Across his career, Jesse has been involved in developing three first-of-their-kind cancer diagnostic products. The constant friction wasn't the science — it was getting samples that actually performed. NGSS is the company he wishes had existed.
"The right clinical samples are always the main issue in cancer diagnostics."
Advisory Team
Operators from across the liquid-biopsy ecosystem.
AM
Dr. Abigail McElhinny
AOA Dx
SG
Mr. Scott Gotshall
WatchMaker
Traction & Momentum
Validated by the market. Ready to sell.
Market Validation
- Substantial bottlenecks confirmed
- Large sample cohorts are lacking
Product Validation
- Ranked #1 in usefulness
- Validated pricing
Strategic Momentum
- Supply discussions underway
- Regulatory & lab milestones in progress
The VisionPartner with us
NGSS: Enabling Progress.
With $500K seed funding, NGSS will set up its lab, obtain certifications, complete proof-of-concept and validation, and procure $4M+ of characterized inventory — driving toward $1.6M in first-year revenue and a potential exit in 5 years.
$500K
Seed Funding
$4M+
Inventory Procured
$1.6M
Yr1 Revenue
$50–100M
5-Yr Exit Range